Literature DB >> 26611201

Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine.

Ryan C McComb1, Mikhail Martchenko2.   

Abstract

Anthrax is defined by the Centers for Disease Control and Prevention as a Category A pathogen for its potential use as a bioweapon. Current prevention treatments include Anthrax Vaccine Adsorbed (AVA). AVA is an undefined formulation of Bacillus anthracis culture supernatant adsorbed to aluminum hydroxide. It has an onerous vaccination schedule, is slow and cumbersome to produce and is slightly reactogenic. Next-generation vaccines are focused on producing recombinant forms of anthrax toxin in a well-defined formulation but these vaccines have been shown to lose potency as they are stored. In addition, studies have shown that a proportion of the antibody response against these vaccines is focused on non-functional, non-neutralizing regions of the anthrax toxin while some essential functional regions are shielded from eliciting an antibody response. Rational vaccinology is a developing field that focuses on designing vaccine antigens based on structural information provided by neutralizing antibody epitope mapping, crystal structure analysis, and functional mapping through amino acid mutations. This information provides an opportunity to design antigens that target only functionally important and conserved regions of a pathogen in order to make a more optimal vaccine product. This review provides an overview of the literature related to functional and neutralizing antibody epitope mapping of the Protective Antigen (PA) component of anthrax toxin.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anthrax; Bacillus anthracis; Functional mapping; Neutralizing antibody mapping; Protective antigen; Rational vaccine design

Mesh:

Substances:

Year:  2015        PMID: 26611201     DOI: 10.1016/j.vaccine.2015.11.025

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Two approaches for the stabilization of Bacillus anthracis recombinant protective antigen.

Authors:  Ekaterina M Ryabchevskaya; Ekaterina A Evtushenko; Dmitry L Granovskiy; Peter A Ivanov; Joseph G Atabekov; Olga A Kondakova; Nikolai A Nikitin; Olga V Karpova
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

Review 2.  Role of site-directed mutagenesis and adjuvants in the stability and potency of anthrax protective antigen.

Authors:  Mohammed Ali Dahhas; Mohammad A Alsenaidy
Journal:  Saudi Pharm J       Date:  2022-02-25       Impact factor: 4.562

3.  Evaluation of immune response to recombinant Bacillus anthracis LFD1-PA4 chimeric protein.

Authors:  H Mirhaj; H Honari; E Zamani
Journal:  Iran J Vet Res       Date:  2019       Impact factor: 1.376

4.  A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis.

Authors:  Pan Tao; Marthandan Mahalingam; Jingen Zhu; Mahtab Moayeri; Michelle L Kirtley; Eric C Fitts; Jourdan A Andersson; William S Lawrence; Stephen H Leppla; Ashok K Chopra; Venigalla B Rao
Journal:  Front Immunol       Date:  2017-06-26       Impact factor: 7.561

5.  A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.

Authors:  Pan Tao; Marthandan Mahalingam; Jingen Zhu; Mahtab Moayeri; Jian Sha; William S Lawrence; Stephen H Leppla; Ashok K Chopra; Venigalla B Rao
Journal:  mBio       Date:  2018-10-16       Impact factor: 7.867

6.  Anthrax protective antigen is a calcium-dependent serine protease.

Authors:  Lisanne Storm; Floris J Bikker; Kamran Nazmi; Albert G Hulst; Debora V der Riet-Van Oeveren; Enno C I Veerman; John P Hays; Wendy E Kaman
Journal:  Virulence       Date:  2018       Impact factor: 5.882

7.  Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.

Authors:  Theresa B Gallagher; Gabriela Mellado-Sanchez; Ana L Jorgensen; Stephen Moore; James P Nataro; Marcela F Pasetti; Les W Baillie
Journal:  PLoS Negl Trop Dis       Date:  2019-08-20

8.  Single-dose combination nanovaccine induces both rapid and durable humoral immunity and toxin neutralizing antibody responses against Bacillus anthracis.

Authors:  Sean M Kelly; Kristina R Larsen; Ross Darling; Andrew C Petersen; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Vaccine       Date:  2021-06-02       Impact factor: 4.169

Review 9.  Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens.

Authors:  Jonathan S LeCureux; Gregg A Dean
Journal:  mSphere       Date:  2018-05-16       Impact factor: 4.389

Review 10.  Inhibition of Pore-Forming Proteins.

Authors:  Neža Omersa; Marjetka Podobnik; Gregor Anderluh
Journal:  Toxins (Basel)       Date:  2019-09-19       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.